#mounjaro #ozempicweightloss #ozempic #yahoofinance
Shares of Novo Nordisk (NVO) are falling after a new study found that Eli Lilly's (LLY) GLP-1 weight-loss drug tirzepatide (Mounjaro) leads to faster and greater weight loss results than semaglutide (Ozempic). Yahoo Finance Senior Reporter Anjalee Khemlani breaks down the study and how it's affecting Novo Nordisk's stock valuation. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Melanie Riehl
Yahoo Finance: Market Coverage, Stocks, & Business News
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
- Get the latest news and data at finance.yahoo.com
- Download the Yahoo Finance app on Apple ([ Ссылка ]) or Android ([ Ссылка ])
- Follow Yahoo Finance on social:
X: [ Ссылка ]
Instagram: [ Ссылка ]
TikTok: [ Ссылка ]
Facebook: [ Ссылка ]
LinkedIn: [ Ссылка ]
